NOVARTIS AG
CIK 1114448 · last filed 2020-07-16
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.66B
Companies
14
Total Filings
46
Lifetime Open-Market Net
$7.62M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Poseida Therapeutics, Inc. (PSTX) Delisted | 10%+ Owner | 5,908,089 | $9.50 | $56.13M | $0 | 1 | 2020-07-16 |
| Akouos, Inc. (AKUS) Delisted | 856,262 | $13.29 | $11.38M | $4.25M | 1 | 2020-07-02 | |
| GRTX | 10%+ Owner | 17,448 | $17.60 | $307.1K | -$729.4K | 2 | 2020-06-12 |
| Whitehawk Therapeutics, Inc. (ARPO) Delisted | 10%+ Owner | 346,207 | $33.00 | $11.42M | -$695.9K | 2 | 2019-04-05 |
| Rein Therapeutics, Inc. (ALRN) Delisted | 10%+ Owner | 121,739 | $2.11 | $256.9K | $7.47M | 6 | 2018-08-16 |
| ALT | 10%+ Owner | 186,579 | $2.99 | $557.9K | $0 | 4 | 2018-06-15 |
| NTLA | 10%+ Owner | 4,129,903 | $10.89 | $44.97M | -$45.74M | 3 | 2017-12-14 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | 10%+ Owner | 2,307,877 | — | — | $781.6K | 4 | 2017-06-12 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | 10%+ Owner | 2,310,924 | $12.01 | $27.75M | $6.00M | 1 | 2016-04-12 |
| KINETA, INC./DE (PTI) Delisted | 10%+ Owner | 74,940 | — | — | $6.00M | 1 | 2016-02-17 |
| Eledon Pharmaceuticals, Inc. (TKAI) Delisted | 10%+ Owner | 502,765 | — | — | $5.56M | 5 | 2015-07-15 |
| IDENIX PHARMACEUTICALS INC (IDIX) Delisted | 33,185,191 | — | — | $10.23M | 9 | 2011-04-13 | |
| Adhera Therapeutics, Inc. (MRNAD) Delisted | 10%+ Owner | 2,804,670 | — | — | -$619.8K | 3 | 2011-01-25 |
| ALNY | 10%+ Owner | 5,602,898 | $288.41 | $1.62B | $15.11M | 3 | 2010-04-26 |
Recent Filings · Page 3 of 5
46 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-03-07 | NTLA | Other (J) | +158,490 | $0 | EDGAR |
| 2016-10-31 | Ra Pharmaceuticals, Inc. (RARX) Delisted | Mixed | +5,091,304 | $2.20M | EDGAR |
| 2016-05-11 | NTLA | Mixed | +11,147,316 | $10.00M | EDGAR |
| 2016-04-12 | Spyre Therapeutics, Inc. (AGLE) Delisted | Mixed | +4,621,848 | $6.00M | EDGAR |
| 2016-02-17 | KINETA, INC./DE (PTI) Delisted | Mixed | +3,747,582 | $6.00M | EDGAR |
| 2015-07-15 | Eledon Pharmaceuticals, Inc. (TKAI) Delisted | Sell (S) | −96,944 | -$1.39M | EDGAR |
| 2015-06-16 | Eledon Pharmaceuticals, Inc. (TKAI) Delisted | Sell (S) | −41,392 | -$587.8K | EDGAR |
| 2015-06-12 | Eledon Pharmaceuticals, Inc. (TKAI) Delisted | Sell (S) | −55,750 | -$791.6K | EDGAR |
| 2015-03-20 | Eledon Pharmaceuticals, Inc. (TKAI) Delisted | Sell (S) | −98,282 | -$1.43M | EDGAR |
| 2014-09-24 | Eledon Pharmaceuticals, Inc. (TKAI) Delisted | Mixed | +9,288,656 | $9.75M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.